nils-herrmann/clean_scirepeval huggingface dataset:
Pulmonary Rehabilitation in COPD: Effect of 2 Aerobic Exercise Intensities on Subject-Centered Outcomes--A Randomized Controlled Trial.

Exercise training is an important component of pulmonary rehabilitation, but it remains questionable how training intensity affects patient-centered outcomes. The aim of this study was to compare the effects of 2 aerobic training intensities on health-related quality of life (HRQOL), symptom control, and exercise tolerance in subjects with COPD.



Thirty-four subjects with mild to very severe COPD participated in an equivalence/non-inferiority randomized controlled trial with a parallel group blinded to 60 or 80% maximum work rate (W max) aerobic training intensity. The intervention was an out-patient pulmonary rehabilitation program conducted 3 times/week for 8 weeks. Outcomes were assessed with the St George Respiratory Questionnaire (primary outcome), Mahler's dyspnea index, London Chest Activity of Daily Living scale, 6-min walk test, and constant-load and incremental exercise tests.



Subjects were randomly allocated to aerobic training intensity of 60% W max (group 1, n = 17) or 80% W max (group 2, n = 17). Although there were significant improvements in all outcomes for both groups, there were no between-group differences in mean change in the St George Respiratory Questionnaire (P = .31, 95% CI -12.0 to 3.9), Mahler's dyspnea index (P = .38), London Chest Activity of Daily Living scale (P = .92), 6-min walk test (P = .50, 95% CI 6.2-71.1), constant-load exercise test (P = .50), and incremental exercise test (P = .12). There was only one exercise-related adverse event of cardiac symptoms.



Aerobic training intensity of at least 60% W max has a positive impact on COPD patient-centered outcomes, with no additional benefit of increasing intensity to 80% W max in HRQOL, symptom control, and exercise tolerance, challenging the present clinical attitude of rehabilitation professionals.
Power in unity: forming teams in large-scale community systems

The internet has enabled the collaboration of groups at a scale that was unseen before. A key problem for large collaboration groups is to be able to allocate tasks effectively. An effective task assignment method should consider both how fit teams are for each job as well as how fair the assignment is to team members, in terms that no one should be overloaded or unfairly singled out. The assignment has to be done automatically or semi-automatically given that it is difficult and time-consuming to keep track of the skills and the workload of each person. Obviously the method to do this assignment must also be computationally efficient.
 In this paper we present a general framework for task assignment problems. We provide a formal treatment on how to represent teams and tasks. We propose alternative functions for measuring the fitness of a team performing a task and we discuss desirable properties of those functions. Then we focus on one class of task-assignment problems, we characterize the complexity of the problem, and we provide algorithms with provable approximation guarantees, as well as lower bounds. We also present experimental results that show that our methods are useful in practice in several application scenarios.
MR mammography using diffusion-weighted imaging in evaluating breast cancer: a correlation with proliferation index

To evaluate whether the variation of the apparent diffusion coefficient (ADC) values obtained with DWI can predict elevated levels of Ki67 proliferation index and aggressive subtypes in patients with breast cancer. Breast MRI studies of 115 patients (mean age 57.3 years, range 36–81 years) with a biopsy-proven breast cancers were evaluated in this retrospective IRB-approved study. Examinations were performed on a 1.5 T magnet and included a Single-Shot Echoplanar DWI sequence with b values of 0 and 1000 s/mm2. For each target lesion, ADC was measured. ADC values were compared considering Ki67 status (≥20 % or <20 %), histology, grade (G1, G2 or G3) and clinical–pathological classification (Luminal A, Luminal B HER2-positive, Luminal B HER-2 negative, HER-2 enriched and Triple Negative). Mann–Whitney U test and Kruskal–Wallis test were used for comparisons and receiver operating characteristic (ROC) curves were obtained. Inter- and intra-reader variability was evaluated in a subset of 40 patients, using interclass correlation coefficient (ICC) and Bland–Altman plots. Of 115 lesions, 53 (46.1 %) were assessed as Ki67 positive and 62 (53.9 %) as Ki67 negative. ADC values were significantly (p < 0.0001) lower in Ki67-positive patients (median 0.86 × 10−3 mm2/s; interquartile range 0.75–0.92) compared to Ki67-negative (median 1.03 × 10−3 mm2/s; interquartile range 0.92–1.13). Median ADC was also lower in G2 and G3 cancer and in the Luminal B Her2-negative subtype (p = 0.0015). No differences were found when evaluating histology. ROC curve showed a sensitivity and specificity of 83.0 and 66.1 %, respectively, when using a cutoff of 0.95 s/mm2 to differentiate Ki67-positive from Ki67-negative cancers. Inter- and intra-reader variability was moderate (ICC = 0.623; ICC = 0.548, respectively). No systematic differences were identified with Bland–Altman plots. Lower ADC values are associated with elevated Ki67 proliferation index and more aggressive pathologic features. Moderate agreement in ADC measurement could be a limitation.
Analysis of cause-specific mortality in the Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) study.

Expectations that reestablishing and maintaining sinus rhythm in patients with atrial fibrillation might improve survival were disproved in the Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) study. This report describes the cause-specific modes of death in the AFFIRM treatment groups.



All deaths in patients enrolled in AFFIRM underwent blinded review by the AFFIRM Events Committee, and a mode of death was assigned. In AFFIRM, 2033 patients were randomized to a rhythm-control strategy and 2027 patients to a rate-control strategy. During a mean follow-up of 3.5 years, there were 356 deaths in the rhythm-control patients and 310 deaths in the rate-control patients (P=0.07). In the rhythm-control group, 129 patients (9%) died of a cardiac cause, and in the rate-control group, 130 patients (10%) died (P=0.95). Both groups had similar rates of arrhythmic and nonarrhythmic cardiac deaths. The numbers of vascular deaths were similar in the 2 groups: 35 (3%) in the rhythm-control group and 37 (3%) in the rate-control group (P=0.82). There were no differences in the rates of ischemic stroke and central nervous system hemorrhage. In the rhythm-control group, there were 169 noncardiovascular deaths (47.5% of the total number of deaths), whereas in the rate-control arm, there were 113 noncardiovascular deaths (36.5% of the total number of deaths) (P=0.0008). Differences in noncardiovascular death rates were due to pulmonary and cancer-related deaths.



Management of atrial fibrillation with a rhythm-control strategy conferred no advantage over a rate-control strategy in cardiac or vascular mortality and may be associated with an increased noncardiovascular death rate.
Validation of a prediction rule for development of rheumatoid arthritis in patients with early undifferentiated arthritis.

To validate a model which predicts progression from undifferentiated arthritis (UA) to RA, in a Canadian UA cohort.



The prediction rule, comprising variables which are scored from 0 to 13, with higher scores reflecting an increased risk of RA, was applied to baseline characteristics of all patients with UA. Progression to RA was determined at 6 months.



105 patients were identified. By 6 months, 80 (76%) had developed RA while 25 (24%) had developed another diagnosis. Number of tender and swollen joints, rheumatoid factor positivity, anti-cyclic citrullinated peptide positivity, poor functional status and high disease activity were associated with development of RA (p<0.01). Median prediction score was 8.0 for progressors, 5.0 for non-progressors. With these cut-off points, 18 (72%) patients with scores < or =5 did not develop RA, while 35 (97%) with scores > or =8 did develop RA.



High scores in our cohort predicted those who progressed to RA by 6 months. Baseline scores > or =8 corresponded with higher rates of progression.
Efficacy comparison of levocetirizine vs montelukast in ragweed sensitized patients.

To date, no adequate data are available on direct comparison of the efficacy of levocetirizine, a recently approved histamine1-antihistamine, with that of a leukotriene antagonist in the treatment of seasonal allergic rhinitis (SAR) symptoms.



To compare the efficacy of therapeutic doses of 5 mg of levocetirizine and 10 mg of montelukast in ragweed sensitized patients.



A randomized, double-blind, placebo-controlled, parallel-group study was conducted between July and October 2006. Symptomatic patients with SAR were exposed to ragweed pollen under controlled conditions in an environmental exposure chamber for 4 to 5 hours after treatment with 5 mg of levocetirizine, 10 mg of montelukast, or matched placebo on 2 consecutive days. The mean change from baseline in pollen-induced rhinitis symptoms, expressed as a major symptoms complex (MSC) score (sum of scores for rhinorrhea, itchy nose, sniffles, nose blows, sneezes, and watery eyes), in period 1 (first 5 hours after first drug intake) was the primary efficacy outcome.



A total of 611 patients were screened, of whom 403 were randomized to receive treatment (102 placebo, 152 levocetirizine, and 149 montelukast). The MSC score in period 1 was progressively decreased to a significantly greater extent in the levocetirizine group compared with the montelukast and placebo groups (adjusted mean differences, -2.18 [95% confidence interval, -3.35 to -1.01; P < .001] and -2.22 [95% confidence interval, -3.51 to -0.92; P < .001] for levocetirizine vs montelukast and vs placebo, respectively). The effect of 10 mg of montelukast was not significantly different compared with placebo. Levocetirizine also achieved a significantly faster onset of action within 2.5 hours of administration. Both products were well tolerated.



This study in an environmental exposure chamber confirms the therapeutic efficacy of 5 mg of levocetirizine in improving symptoms of SAR, which was superior to 10 mg of montelukast.
The study on mat with hardness and elasticity for minimizing fatigue at various qork conditions

In order to identify the changes in the body the experiment was conducted by maintaining the standing posture for two hours by using three sorts of shoes state and four sorts of mats as an object of 9 test subjects. The Mat used in the experiment was designed on the basis of Elasticity 15% and 35%, Hardness 25Hs and 45Hs. As to the state of shoes, the experiment was progressed by dividing into three sorts of working environment: bare foot, wearing safety shoes and wearing slippers. The measuring of EMG was executed as an object of Erector Spinae, Rectus Femoris, Vastus Lateralis, Tibialis Anterior and Gastrocnemius Medialis. And, the Circumference of Leg, the circumference of crus was measured based on each projecting point of calf, and the circumference of thigh based on the center point of thigh.  The results showed that the elasticity, hardness, and interaction between elasticity and hardness have significant differences at the Erector Spinae, Rectus Femoris with barefoot (p<0.05). The elasticity, hardness, and interaction between elasticity and hardness have significant differences at the Rectus Femoris, Vastus Lateralis with safety shoes (p<0.05). The elasticity, hardness, and interaction between elasticity and hardness have significant differences at the Rectus Femoris with slippers (p<0.05).
Comparison of calcium acetate with calcium carbonate as phosphate binder in patients on maintenance haemodialysis.

Hyperphosphatemia is common in end-stage renal disease patients. Objective of this study is to compare the hypercalcaemic effect and phosphate binding power of calcium acetate and calcium carbonate in end-stage renal disease patients on maintenance haemodialysis.



This randomised control trial was conducted in four phases with calcium acetate or calcium carbonate. Sixty-four patients on haemodialysis were randomly divided into 2 groups. After a washout period of 2 weeks, each group was given calcium acetate or calcium carbonate for 2 months. After another washout period the patients were crossed over and again received these drugs for 2 months. Serum Calcium, phosphate, and albumin were analysed on Selectra E auto analyser at completion of each phase of study. Hypercalcaemic effect was defined as serum calcium > 2.54 mmol/l, and phosphate binding power as serum phosphate < 1.61 mmol/l.



Forty-one patients completed the study. Though lower dose of calcium acetate was used, it resulted in equally good control of hyperphosphatemia as compared with calcium carbonate therapy [1.37 mmol/l (SD 0.33) vs. 1.46 mmol/l (SD 0.34), p = 0.16]. Incidence of hypercalcaemia was higher with calcium carbonate therapy (2.73 +/- 0.67 mmol/l vs. 2.32 +/- 0.28 mmol/l, p < 0.01). Both drugs were well tolerated, but patients more frequently complained of muscle cramps while taking calcium acetate.



It is concluded that calcium acetate has similar effect on serum phosphate levels as compared to calcium carbonate in patients on maintenance haemodialysis. However, calcium acetate results in lesser frequency of hypercalcaemia as compared to calcium carbonate. Tolerance to both drugs was similar, though patients complained of more muscle cramps while taking calcium acetate.
Salmeterol plus fluticasone propionate versus fluticasone propionate plus montelukast: a randomised controlled trial investigating the effects on airway inflammation in asthma

Few studies have compared treatment strategies in patients with asthma poorly controlled on low dose inhaled corticosteroids, and little is known about the effects of different treatments on airway inflammation. In this double-blind, placebo-controlled, parallel group study, we compared the effects of salmeterol plus fluticasone propionate (FP) (Seretide; SFC) and FP plus montelukast (FP/M) on sputum inflammatory markers, airway responsiveness, lung function, and symptoms in adult asthmatics.



Sixty-six subjects were randomised to SFC or FP/M for 12 weeks. The primary outcome was changes in neutrophil, eosinophil, macrophage, lymphocyte, and epithelial cell levels in induced sputum. Additional outcomes included the change in other sputum markers of airway inflammation, airway responsiveness, symptom control, and lung function.



Both treatments had no significant effect on induced sputum inflammatory cells, although there was a trend for a reduction in sputum eosinophils. Both treatments significantly improved airway responsiveness, whereas SFC generally led to greater improvements in symptom control and lung function than FP/M. FP/M led to significantly greater reductions in sputum cysteinyl leukotrienes than SFC (treatment ratio 1.80; 95% CI 1.09, 2.94).



Both treatments led to similar control of eosinophilic airway inflammation, although PEF and symptom control were better with SFC.  (SOLTA).
Validation of the Brazilian version of the quality of life scale for patients with Alzheimer's disease and their caregivers (QOL-AD).

Quality of life (QOL) has been extensively studied in clinical trials and in research on chronic degenerative diseases and dementia. The aim of this study was to assess the reliability and construct validity of the Brazilian version of the QOL scale in Alzheimer's disease (AD; QOL-AD). The QOL-AD was administered to 60 patients with mild or moderate AD and to their caregivers. The construct validation was accomplished through correlations amongst total scores of patients' and caregivers' reports on patients' quality of life (PQOL and C-PQOL, respectively), and data related to cognitive impairment, depressive symptoms, functional performance, behavioral disturbances and a generic instrument of quality of life (WHOQOL-brief), as well as correlation of total score of caregivers' reports on their own quality of life (CQOL) with the measurements cited above, QOL-AD patient reports, and depressive symptoms. The reliability was high for PQOL, C-PQOL, and CQOL versions (Cronbach's alpha = 0.80, 0.83, and 0.86, respectively). We observed significant correlations in the construct validity of all three versions regarding the variables associated with the disease and also with WHOQOL-brief. The scale took, on average, six min for each version. The results indicate reliability and construct validity of the Brazilian version of the QOL-AD in the studied sample.
Validation and reproducibility of aortic pulse wave velocity as assessed with velocity-encoded MRI.

To validate magnetic resonance imaging (MRI) assessment of aortic pulse wave velocity (PWV(MRI)) with PWV determined from invasive intra-aortic pressure measurements (PWV(INV)) and to test the reproducibility of the measurement by MRI.



PWV(MRI) was compared with PWV(INV) in 18 nonconsecutive patients scheduled for catheterization for suspected coronary artery disease.  was tested in 10 healthy volunteers who underwent repeated measurement of PWV(MRI) at a single occasion. Velocity-encoded MRI was performed on all participants to assess PWV(MRI) in the total aorta (Ao(total)), the proximal aorta (Ao(prox)), and the distal aorta (Ao(dist)).



The results are expressed as mean +/- SD, Pearson correlation coefficient (PCC), and intraclass correlation (ICC). Good agreement between PWV(MRI) and PWV(INV) was found for Ao(total) (6.5 +/- 1.1 m/s vs. 6.1 +/- 0.8 m/s; PCC = 0.53), Ao(prox) (6.5 +/- 1.3 m/s vs. 6.2 +/- 1.1 m/s; PCC = 0.69), and for Ao(dist) (6.9 +/- 1.1 m/s vs. 6.1 +/- 1.0 m/s; PCC = 0.71). Reproducibility of PWV(MRI) was high for Ao(total) (4.3 +/- 0.5 m/s vs. 4.6 +/- 0.7 m/s; ICC = 0.90, P < 0.01), Ao(prox) (4.3 +/- 0.9 m/s vs. 4.7 +/- 1.0 m/s; ICC = 0.87, P < 0.01), and Ao(dist) (4.3 +/- 0.6 m/s vs. 4.4 +/- 0.8 m/s; ICC = 0.92, P < 0.01).



MRI assessment of aortic pulse wave velocity shows good agreement with invasive pressure measurements and can be determined with high reproducibility.
Training paramedics in focussed echo in life support.

The aim of this study was to determine whether paramedics can be trained to perform and interpret focussed Echo in Life Support (ELS) for the assessment of cardiac movement and the recognition of reversible causes of cardiac arrest.



This study is a prospective observational pilot study. Data were collected during a 1-day course training 11 paramedics to perform ELS scans on healthy volunteers. The students were assessed on image acquisition skills and theoretical knowledge (including interpretation). Level 1 ultrasound-trained emergency medicine physicians undertook the training and assessment.



All paramedics could obtain images in the parasternal and subxiphoid views. When performing scans in the 10-s pulse check window, 88% of attempts in both views were successful (subxiphoid mean image quality 3.8 out of 5, parasternal 4.0). Theoretical knowledge improved (mean precourse score 54%, postcourse score 89%; P<0.001). There was no apparent association between theoretical and practical performances. At 10 weeks, theoretical knowledge was nonsignificantly reduced (82%; P=0.13) but less when compared with practical performance (75% subxiphoid success, mean quality 3.0; 25% parasternal success, mean quality 4.0).



Paramedics can perform focused ELS, integrate attempts into simulated cardiac arrest scenarios and retain some of this knowledge. Further work is required to assess the feasibility of incorporating this into real-world cardiac arrest management.
Validation of Edinburgh postnatal depression scale for adolescent mothers

The Edinburgh Postnatal Depression Scale has widespread use internationally with adult women, but few psychometric properties have been described for samples of adolescent mothers. The purpose of this paper is to validate the psychometric properties of the EPDS in a sample of adolescent mothers (n = 149) in a southern, urban area of the United States. Internal consistency reliability was .88. Principal components analysis supported a two factor structure accounting for 60% of variance. Results of item response theory analysis suggest that the EPDS and the Center for Epidemiologic Studies of Depression Scale have similar psychometric properties. This data can be used to provide evidence of construct validity of the EPDS. The study provides a foundation for further psychometric testing of the instrument.
Association of epicardial adipose tissue with progression of coronary artery calcification is more pronounced in the early phase of atherosclerosis: results from the Heinz Nixdorf recall study.

This study sought to determine whether epicardial adipose tissue (EAT) volume predicts the progression of coronary artery calcification (CAC) score in the general population.



EAT predicts coronary events and is suggested to influence the development of atherosclerosis.



We included 3,367 subjects (mean age 59 8 years; 47% male) from the population-based Heinz Nixdorf Recall study without known coronary artery disease at baseline. CAC was quantified from noncontrast cardiac electron beam computed tomography at baseline and after 5 years. EAT was defined as fat volume inside the pericardial sac and was quantified from axial computed tomography images. Association of EAT volume with CAC progression (log[CAC(follow-up) + 1] - log[CAC(baseline) + 1]) was depicted as percent progression of CAC + 1 per SD of EAT.



Subjects with progression of CAC above the median had higher EAT volume than subjects with less CAC change (101.1 ± 47.1 ml vs. 84.4 43.4 ml; p < 0.0001). In regression analysis, 6.3% (95% confidence interval [CI]:2.3% to 10.4%; p = 0.0019) of progression of CAC + 1 was attributable to 1 SD of EAT, which persisted after adjustment for risk factors (6.1% [95% CI: 1.2% to 11.2%]; p ¼ 0.014). For subjects with a CAC score of >0 to ≤100, progression of CAC þ 1 by 20% (95% CI: 11% to 31%; p < 0.0001) was attributable to 1 SD of EAT. Effect sizes decreased with CAC at baseline, with no relevant link for subjects with a CAC score ≤400 (0.2% [95% CI: -3.5% to 4.2%]; p = 0.9). Likewise, subjects age <55 years at baseline showed the strongest association of EAT with CAC progression (20.6% [95% CI: 9.7% to 32.5%]; p < 0.0001). Interestingly, the effect of EAT on CAC progression was more pronounced in subjects with low body mass index (BMI), and decreased with degree of adiposity (BMI ≤25 kg/m(2):19.8% [95% CI: 9.2% to 31.4%]; p = 0.0001, BMI >40 kg/m(2): 0.8% [95% CI: -26.7% to 38.9%]; p = 0.96).



EAT is associated with the progression of CAC, especially in young subjects and subjects with low CAC score, suggesting that EAT may promote early atherosclerosis development.